Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Breast Neoplasms 3 Prostatic Neoplasms 2 Fallopian Tube Neoplasms 2 Uterine Neoplasms 1 Sarcoma 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1 MMR-D/MSI-H Colorectal Cancers 1 Lymphoma 1 Leiomyosarcoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Cystadenocarcinoma, Serous 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1

Interventions

Rituximab 20 Cyclophosphamide 18 Etoposide 11 Vincristine 10 Doxorubicin 10 fludarabine phosphate 9 Prednisone 9 Filgrastim 9 Radiotherapy 8 Peripheral Blood Stem Cell Transplantation 8 Cytarabine 8 Methotrexate 7 Melphalan 7 Dexamethasone 6 fludarabine 4 Cyclosporine 4 Antilymphocyte Serum 4 duvelisib 3 belinostat 3 Thiotepa 3 Tacrolimus 3 Nivolumab 3 Mycophenolic Acid 3 Lenalidomide 3 Ifosfamide 3 Gemcitabine 3 Carmustine 3 Busulfan 3 Alemtuzumab 3 sargramostim 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Lymphoma × niraparib × Clear all

NCT01244009 2016-11-07

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Tesaro, Inc.

Phase 2 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡